TNF and rheumatoid arthritis: Anti‐tumor necrosis factor (anti‐TNF) agents provide an effective treatment option for patients with RA.1, 2 Certolizumab pegol (CZP) is a humanized anti‐TNF antibody fragment conjugated to polyethylene glycol, approved for the treatment of inflammatory diseases, including RA.3 Early treatment of patients with CZP has been associated with a reduction in inflammation, inhibition of structural damage and improved long‐term outcomes.4, 5 Recent studies have investigated whether the clinical benefits of early CZP treatment are maintained following CZP withdrawal.